|Day Low/High||123.79 / 125.50|
|52 Wk Low/High||105.19 / 194.56|
Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.
BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.
Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene's investigational anti-programmed cell death protein 1 (PD-1) inhibitor,...
Currency manipulation, dumping and intellectual property are crucial themes for the meeting.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.